Navigation Links
The Market for Squamous Cell Carcinoma of the Head and Neck is Characterized by High Unmet Need of Treatment Options Based on Specific Tumor Biology
Date:2/5/2013

BURLINGTON, Mass., Feb. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the market for squamous cell carcinoma of the head and neck (SCCHN) in the United States and Europe will continue to face a high unmet need for targeted therapies aimed at specific subsets of patients, including those with human papillomavirus (HPV)-positive and Epstein-Barr virus (EBV)-positive disease. According to interviewed experts, although emerging therapies are being studied in patients with known HPV or EBV status, the pipeline for drug development in these areas remains sluggish.

"Extending overall survival remains an important unmet need among SCCHN patients and will likely be achieved by identifying and targeting treatments based on a patient's specific tumor biology," said Decision Resources Analyst Regina Jammen , M.S. "Although HPV, EBV and EGFR (epithelial growth factor [receptor]) are validated biomarkers, knowledge of such tumor characteristics does not necessarily inform treatment choice at this time. Developing treatments based on a tumor's particular characteristics will likely optimize therapy and minimize over- and under-treatment. However, with few treatments expected to launch for SCCHN, a high level of unmet need will persist throughout our study period."

According to the Niche Markets and Rare Diseases report entitled Niche Markets and Rare Diseases: Squamous Cell Carcinoma of the Head and Neck, three therapies are expected to launch over the forecast period for treatment of SCCHN – Boehringer Ingelheim's Tovok/Tomtovok (afatinib), CEL-SCI's Multikine and Oncolytics Biotech's Reolysin – each from a different drug class. Afatinib, an orally administered EGFR inhibitor, will find broad use across several subsets of SCCHN patients. Reolysin, an oncolytic virus, will be used as a second-line therapy for patients with oropharynx, oral cavity, larynx and hypopharynx tumors or squamous cell nasopharynx cancer. And, Multikine, a novel agent with immunostimulatory activity, could address some of the unmet needs of patients with stage III and IVA oral cavity and soft palate tumors.

"Afatinib and Reolysin will expand the second-line treatment options for patients with recurrent/metastatic disease," said Ms. Jammen. "But, none of the three new therapies will dramatically change current treatment practices."

About Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources GroupAllison Thrower

Liz Marshall781-993-2604

781-993-2563athrower@dresourcesgroup.com 

emarshall@dresourcesgroup.com 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Wacoms DTH-2242: An Ideal Interactive Pen and Touch Display Solution for Healthcare and Presentation Markets
2. Millennium Research Group Identifies the Top Ten Trends in Medical Device Markets for 2013
3. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
4. iBio Announces At-the-Market Equity Offering
5. Monoclonal Antibody Industry 2013 Global and China Market Analysis in New Research Report at RnRMarketResearch.com
6. Wound and Tissue Management Market in Brazil: Abridged Competitive Analysis, Partial Numerical Data, CAGRs And Qualitative Synopses in New Research Report at ReportsnReports.com
7. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
8. Pressure Relief Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
9. Asia Pacific Hospital Supplies Market Outlook to 2018 - Disposable Hospital Supplies, Mobility Aids and Transportation Equipment, Operating Room Equipment, Sterilization and Disinfectant Equipment and Others
10. North America Wound Care Management Market Outlook to 2018 - Advanced Wound Management, Wound Closure Devices, Pressure Relief Devices, Ostomy Drainage Bags and Other
11. Asia-Pacific Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 Site ... Today, VoicePower Ltd - The Speech Recognition People, announced their latest ... to improve patient care, reduce turnaround times and to save the ... ,- VoicePower client since 2013 Challenge: --> ... --> - Six doctors ,- Wirral CCG ,- VoicePower ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... for structural heart disease and critical care monitoring, announced ... repurchase (ASR) agreement with Morgan Stanley & Co. LLC ... repurchase is part of the Company,s previously authorized program ... common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of ... for this weekend’s Big Game. Take the stress out of your party preparation – ... guests happy at every stage of the game. , “The key to hosting a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
Breaking Medicine News(10 mins):